Unlocking Clinical Trial Velocity
Launching a Phase I or II oncology trial in Europe or the US requires assembling hundreds of pages of complex documentation: patient eligibility criteria, pharmacokinetic protocols, safety surveillance frameworks, and regulatory filings.Oxford-based MedScribe has secured €22M in Series A financing led by Sofinnova Partners and EQT Life Sciences to automate this administrative burden for clinical investigators.Regulatory Clearance from EMA & NHS
MedScribe's specialized models have been trained under strict governance protocols with the UK National Health Service and top European academic research institutions. By ensuring full data provenance, researchers can generate compliant protocols that clear ethical committees 60% faster."Clinical trial delays aren't caused by lack of scientific breakthroughs; they're caused by six-month regulatory paperwork backlogs. MedScribe gets life-saving compounds into patients a year earlier."